account_balance
Investment manager · 13F filer · SEC CIK 2111609
Ishara Investments LP
Reported value$136Mas of Jun 30, 2026
Positions41 16 new, 11 sold out
Top 10 weight51.0%ACAD alone is 8%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ACADAcadia Pharmaceuticals Inc
7.6%Added +233%
XERSXeris Biopharma Holdings Inc
7.2%Added +20%
BMRNBiomarin Pharmaceutical Inc
6.0%Added +75%
PRAXPraxis Precision Medicines I
5.5%
RAREUltragenyx Pharmaceutical In
5.0%Added +18%
AGIOAgios Pharmaceuticals Inc
4.5%New
INSMInsmed Inc
4.0%New
CRNXCrinetics Pharmaceuticals In
3.9%New
ZNTLZentalis Pharmaceuticals Inc
3.7%Trimmed −17%
PCVXVaxcyte Inc
3.5%Added +43%
ANNXAnnexon Inc
3.4%Added +371%
TVTXTravere Therapeutics Inc
3.4%Trimmed −26%
ACADAcadia Pharmaceuticals Inc
7.6%Added +233%
XERSXeris Biopharma Holdings Inc
7.2%Added +20%
BMRNBiomarin Pharmaceutical Inc
6.0%Added +75%
PRAXPraxis Precision Medicines I
5.5%
RAREUltragenyx Pharmaceutical In
5.0%Added +18%
AGIO4.5%INSM4.0%CRNX3.9%
ZNTL3.7%PCVX3.5%ANNX3.4%TVTX3.4%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ACAD Acadia Pharmaceuticals Inc 7.6% Added +233%XERS Xeris Biopharma Holdings Inc 7.2% Added +20%BMRN Biomarin Pharmaceutical Inc 6.0% Added +75%PRAX Praxis Precision Medicines I 5.5% HeldRARE Ultragenyx Pharmaceutical In 5.0% Added +18%AGIO Agios Pharmaceuticals Inc 4.5% NewINSM Insmed Inc 4.0% New
CRNX Crinetics Pharmaceuticals In 3.9% New
ZNTL Zentalis Pharmaceuticals Inc 3.7% Trimmed −17%PCVX Vaxcyte Inc 3.5% Added +43%ANNX Annexon Inc 3.4% Added +371%TVTX Travere Therapeutics Inc 3.4% Trimmed −26%What changed